New pharmacotherapy for the treatment of onychomycosis: an update

Bibliography

• Zaias N. Onychomycosis. Arch Dermatol 1972;105(2):263-74
   PubMedGoogle Scholar
• Welsh O. Onychomycosis. Clin Dermatol 2010;28(2):151-9
   PubMed Web of Science ®Google Scholar
• Baran R. The nail in the elderly. Clin Dermatol 2011;29(1):54-60
   PubMed Web of Science ®Google Scholar
• Gupta AK, Konnikov N, MacDonald P, et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol 1998;139(4):665-71
   PubMed Web of Science ®Google Scholar
• Gupta AK, Humke S. The prevalence and management of onychomycosis in diabetic patients. Eur J Dermatol 2000;10(5):379-84
   PubMed Web of Science ®Google Scholar
• Gupta AK, Gupta MA, Summerbell RC, et al. The epidemiology of onychomycosis: possible role of smoking and peripheral arterial disease. J Eur Acad Dermatol Venereol 2000;14(6):466-9
   PubMed Web of Science ®Google Scholar
• Gupta AK, Taborda P, Taborda V, et al. Epidemiology and prevalence of onychomycosis in HIV-positive individuals. Int J Dermatol 2000;39(10):746-53
   PubMed Web of Science ®Google Scholar
• Bakr NI, El-Sawy E, Hamdy AF, Bakr MA. Skin infections in Egyptian renal transplant recipients. Transpl Infect Dis 2011;13(2):131-5
   PubMed Web of Science ®Google Scholar
• Döner N, Yaşar Ş, Ekmekçi TR. Evaluation of obesity-associated dermatoses in obese and overweight individuals. Turkderm 2011;45(3):146-51
   Google Scholar
• Gupta AK, Simpson FC. Investigational drugs for onychomycosis. Expert Opin Investig Drugs 2014;23(1):97-106
   PubMed Web of Science ®Google Scholar
• Gupta AK, Paquet M, Simpson FC. Therapies for the treatment of onychomycosis. Clin Dermatol 2013;31(5):544-54
   PubMed Web of Science ®Google Scholar
• Novartis. LAMISIL (terbinafine hydrochloride) Tablets, 250 mg [Internet]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020539s021lbl.pdf
   Google Scholar
• Tosti A, Piraccini BM, Stinchi C, Colombo MD. Relapses of onychomycosis after successful treatment with systemic antifungals: a three-year follow-up. Dermatology 1998;197(2):162-6
   PubMed Web of Science ®Google Scholar
• Arrese JE, Piérard GE. Treatment failures and relapses in onychomycosis: a stubborn clinical problem. Dermatology 2003;207(3):255-60
   PubMed Web of Science ®Google Scholar
• Pierard GE, Pierard-Franchimont C, Arrese JE. The boosted antifungal topical treatment (BATT) for onychomycosis. Med Mycol 2000;38(5):391-2
   PubMed Web of Science ®Google Scholar
• Pierard GE. Spores, sporodochia and fomites in onychomycosis. Dermatology 2006;213(2):169-72
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, van Rossem K, Malahias S, Raterink K. A phase II, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to investigate the efficacy and safety of 4 dose regimens of oral albaconazole in patients with distal subungual onychomycosis. J Am Acad Dermatol 2013;69(3):416-25
   PubMed Web of Science ®Google Scholar
• Schering Plough. NOXAFIL® (Posaconazole) oral suspension 40 mg/mL [Internet]. 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022003s011s012,022027s002s003lbl.pdf
   Google Scholar
• Elewski B, Pollak R, Ashton S, et al. A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis. Br J Dermatol 2012;166(2):389-98
   PubMed Web of Science ®Google Scholar
• Valeant Pharmaceuticals. JUBLIA® (efinaconazole) topical solution, 10% [Internet]. 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203567s000lbl.pdf
   Google Scholar
• Valeant Canada LP. PrJUBLIATM Efinaconazole Topical Solution, 10% w/w. 2013
   Google Scholar
• Tschen EH, Bucko AD, Oizumi N, et al. Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2, multicenter, randomized, double-blind study. J Drugs Dermatol 2013;12(2):186-92
   PubMed Web of Science ®Google Scholar
• Elewski BE, Rich P, Pariser DM, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol 2013;68(4):600-8
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Ghannoum M. Therapeutic potential of TDT 067 (terbinafine in Transfersome®): a carrier-based dosage form of terbinafine for onychomycosis. Expert Opin Investig Drugs 2012;21(10):1549-62
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Isham N, Herbert J, et al. Activity of TDT. 067 (Terbinafine in Transfersome) against agents of onychomycosis, as determined by minimum inhibitory and fungicidal concentrations. J Clin Microbiol 2011;49(5):1716-20
   PubMed Web of Science ®Google Scholar
• Dominicus R, Weidner C, Tate H, Kroon H-A. Open-label study of the efficacy and safety of topical treatment with TDT 067 (terbinafine in Transfersome®) in patients with onychomycosis. Br J Dermatol 2012;166(6):1360-2
   PubMed Web of Science ®Google Scholar
• Anacor Pharmaceuticals, Inc. KERYDIN(TM) (tavaborole) topical solution, 5% [Internet]. 2014. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
   Google Scholar
• Rock FL, Mao W, Yaremchuk A, et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 2007;316(5832):1759-61
   PubMed Web of Science ®Google Scholar
• Zane L, Pollak R. Safety and efficacy of tavaborole (Formerly AN2690), a novel boron-based molecule, in phase 2 trials for the topical treatment of toenail onychomycosis [Internet]. Anacor Pharmaceuticals, Washington, DC; 2012. Available from: http://www.anacor.com/pdf/APMA%20Tavaborole%20Phase%202%20Poster.pdf [Cited 11 April 2013]
   Google Scholar
• Harris F, Pierpoint L. Photodynamic therapy based on 5-aminolevulinic acid and its use as an antimicrobial agent. Med Res Rev 2012;32(6):1292-327
   PubMed Web of Science ®Google Scholar
• Galderma Labs. METVIXIA® (methyl aminolevulinate) Cream, 16.8% [Internet]. 2004. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021415s004lbl.pdf
   Google Scholar
• Kamp H, Tietz H-J, Lutz M, et al. Antifungal effect of 5-aminolevulinic acid PDT in trichophyton rubrum. Mycoses 2005;48(2):101-7
   PubMed Web of Science ®Google Scholar
• Watanabe D, Kawamura C, Masuda Y, et al. Successful treatment of toenail onychomycosis with photodynamic therapy. Arch Dermatol 2008;144(1):19-21
   PubMed Web of Science ®Google Scholar
• Piraccini BM, Rech G, Tosti A. Photodynamic therapy of onychomycosis caused by Trichophyton rubrum. J Am Acad Dermatol 2008;59(5 Suppl):S75-6
   Web of Science ®Google Scholar
• Gilaberte Y, Aspiroz C, Martes MP, et al. Treatment of refractory fingernail onychomycosis caused by nondermatophyte molds with methylaminolevulinate photodynamic therapy. J Am Acad Dermatol 2011;65(3):669-71
   PubMed Web of Science ®Google Scholar
• Sotiriou E, Koussidou-Eremonti T, Chaidemenos G, et al. Photodynamic therapy for distal and lateral subungual toenail onychomycosis caused by Trichophyton rubrum: preliminary results of a single-centre open trial. Acta Derm Venereol 2010;90(2):216-17
   PubMed Web of Science ®Google Scholar
• Silva AP, Kurachi C, Bagnato VS, Inada NM. Fast elimination of onychomycosis by hematoporphyrin derivative-photodynamic therapy. Photodiagn Photodyn Ther 2013;10(3):328-30
   PubMed Web of Science ®Google Scholar
• Souza LW, Souza SV, Botelho AC. Distal and lateral toenail onychomycosis caused by Trichophyton rubrum: treatment with photodynamic therapy based on methylene blue dye. An Bras Dermatol 2014;89(1):184-6
   PubMed Web of Science ®Google Scholar
• Souza LW, Souza SV, Botelho AC. Endonyx toenail onychomycosis caused by Trichophyton rubrum: treatment with photodynamic therapy based on methylene blue dye. An Bras Dermatol 2013;88(6):1019-21
   PubMed Web of Science ®Google Scholar
• Mehra T, Schaller M, Walker B, et al. Efficacy of antifungal PACT in an in vitro model of onychomycosis. J Eur Acad Dermatol Venereol 2014. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Pinpointe USA. 510(k) Summary K093547. PinPointe FootLaser, Pinpointe USA, Inc. [Internet] 2010. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf9/K093547.pdf
   Google Scholar
• Kozarev J, Vižintin Z. Novel laser therapy in treatment of onychomycosis. J Laser Health Acad 2010;2010(1):1-8
   Google Scholar
• Kozarev J. Clearsteps – laser onychomycosis treatment: assessment of efficacy 12 months after treatment and beyond. J Laser Health Acad 2011;2011(1):S07
   Google Scholar
• Harris DM, McDowell BA, Strisower J. Laser treatment for toenail fungus. Proc SPIE 2009;7161:71610M1-7
   Google Scholar
• Weiss D. 3 month clinical results using sub-millisecond 1064 nm Nd:YAG laser for the treatment of onychomycosis [Internet]. 2011. Available from: http://conejofeet.com/wp-content/uploads/2011/06/David-Weiss-DPM-report.pdf
   Google Scholar
• Hochman LG. Laser treatment of onychomycosis using a novel 0.65-millisecond pulsed Nd:YAG 1064-nm laser. J Cosmet Laser Ther 2011;13(1):2-5
   PubMed Web of Science ®Google Scholar
• Kimura U, Takeuchi K, Kinoshita A, et al. Treating onychomycoses of the toenail: clinical efficacy of the sub-millisecond 1,064 nm Nd: YAG laser using a 5 mm spot diameter. J Drugs Dermatol 2012;11(4):496-504
   PubMed Web of Science ®Google Scholar
• Waibel J, Rudnick A, Wulkan AJ. Prospective efficacy and safety evaluation of laser treatments with real-time temperature feedback for fungal onychomycosis. J Drugs Dermatol 2013;12(11):1237-42
   PubMed Web of Science ®Google Scholar
• Carney C, Cantrell W, Warner J, Elewski B. Treatment of onychomycosis using a submillisecond 1064-nm neodymium:yttrium-aluminum-garnet laser. J Am Acad Dermatol 2013;69(4):578-82
   PubMed Web of Science ®Google Scholar
• Noguchi H, Miyata K, Sugita T, et al. Treatment of onychomycosis using a 1064nm Nd:YAG laser. Med Mycol J 2013;54(4):333-9
   PubMedGoogle Scholar
• Moon SH, Hur H, Oh YJ, et al. Treatment of onychomycosis with a 1,064-nm long-pulsed Nd:YAG laser. J Cosmet Laser Ther 2014;16(4):165-70
   PubMed Web of Science ®Google Scholar
• Gupta AK, Paquet M. A retrospective chart review of the clinical efficacy of Nd:YAG 1064-nm laser for toenail onychomycosis. J Dermatolog Treat 2014;5:1-3
   Google Scholar
• Ortiz AE, Truong S, Serowka K, Kelly KM. A 1,320-nm Nd: YAG laser for improving the appearance of onychomycosis. Dermatol Surg 2014;40(12):1356-60
   PubMed Web of Science ®Google Scholar
• Gupta AK, Simpson FC. Laser therapy for onychomycosis. J Cutan Med Surg 2013;17(5):301-7
   PubMed Web of Science ®Google Scholar
• Bristow IR. The effectiveness of lasers in the treatment of onychomycosis: a systematic review. J Foot Ankle Res 2014;7:34
   PubMed Web of Science ®Google Scholar
• Light Age, Inc. 510(k) Summary K110370. Q-Clear, Light Age [Internet]. 2011. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf11/K110370.pdf
   Google Scholar
• Kalokasidis K, Onder M, Trakatelli M-G, et al. The effect of Q-switched Nd:YAG 1064 nm/532 nm laser in the treatment of onychomycosis in vivo. Dermatol Res Pract 2013;2013:1-10
   Google Scholar
• Galvan Garcia HR. Onychomycosis: 1064-nm Nd:YAG q-switch laser treatment. J Cosmet Dermatol 2014;13(3):232-5
   PubMed Web of Science ®Google Scholar
• Murdan S. Enhancing the nail permeability of topically applied drugs. Expert Opin Drug Deliv 2008;5(11):1267-82
   PubMed Web of Science ®Google Scholar
• Del Rosso JQ. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. J Clin Aesthet Dermatol 2014;7(7):10-18
   PubMedGoogle Scholar
• Pariser DM, Pollak R, Pillai R, Olin JT. Efinaconazole topical solution may reach the onychomycosis infection site by spreading through the space between the nail plate and nail bed. MauiDerm NP+PA Fall Meeting, Boston, MA; 2014
   Google Scholar
• De Assis Santos D, de Carvalho Araújo RA, Kohler LM, et al. Molecular typing and antifungal susceptibility of Trichophyton rubrum isolates from patients with onychomycosis pre- and post-treatment. Int J Antimicrob Agents 2007;29(5):563-9
   PubMed Web of Science ®Google Scholar
• Gupta AK, Kohli Y. Evaluation of in vitro resistance in patients with onychomycosis who fail antifungal therapy. Dermatology 2003;207(4):375-80
   PubMed Web of Science ®Google Scholar
• Mukherjee P, Leidich S, Isham N, et al. Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine. Antimicrob Agents Chemother 2003;47(1):82-6
   PubMed Web of Science ®Google Scholar